/
ORMP
$4.64-$0.03 (-0.64%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$191.1M
41M shares
52-week range
$1.98 – $5.19
83% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.62%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.7M | $2.7M | $2.7M | $2.7M | $1.3M | $0 | $2.0M |
| Cost of revenue | $86.0K | $90.0K | $90.0K | $0 | $0 | $0 | $193.0K | $2.0M |
| Gross profit | $2.4M | $2.6M | $2.6M | $2.7M | $2.7M | $1.3M | −$193.0K | $13.0K |
| Gross margin | 96.5% | 96.7% | 96.7% | 100.0% | 100.0% | 100.0% | — | 0.7% |
| R&D | $12.0M | $13.5M | $10.2M | $21.0M | $27.6M | $9.0M | $6.3M | $6.4M |
| Operating income | −$13.5M | −$14.6M | −$11.8M | −$24.2M | −$40.6M | −$15.8M | −$12.8M | −$15.1M |
| EBITDA | −$13.5M | −$14.2M | −$11.3M | −$25.0M | −$37.0M | $7.3M | −$14.9M | $75.4M |
| Net income | −$12.7M | −$14.4M | −$11.5M | −$22.2M | −$37.8M | $5.5M | −$19.1M | $64.0M |
| Net margin | -519.7% | -531.1% | -424.8% | -822.7% | -1397.1% | 412.3% | — | 3202.5% |
| EPS (diluted) | -0.86 | -0.82 | -0.56 | -0.78 | -0.97 | 0.14 | -0.47 | 1.50 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $2.31 | $2.31–$2.31 | 1 |
| 2027 | $778593 | $-0.82 | $-0.82–$-0.82 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.18
Price
$4.64
Implied downside
-74%
Peer comparison
Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
www.oramed.com- Employees
- 13
- IPO / List date
- Apr 19, 2004
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds ORMP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 147,700 | $502.2K |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 5.39% ($0.25/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-01-16 | $0.2500 | 2026-01-26 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-01-23 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded ORMP yet.
